Search Results - sars-cov-2

11 Results

Sort By:

Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...

Published: 5/14/2025 | Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington

Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Tempol as a Therapeutic to Treat Covid-19 Via Inhibition of Viral Replication

Abstract: Despite several partially effective prophylactic vaccines for SARS-CoV-2 exist, patients worldwide still succumb to COVID-19. New therapeutics to treat this disease are still needed. Upon host invasion, a critical step in the pathogenesis of COVID-19 is intracellular replication of SARS-CoV-2 before viral particles invade nearby healthy cells....

Published: 4/22/2025 | Inventor(s): Tracey Rouault, William Linehan, Nunziata Maio

Keywords(s): ANTIVIRAL, COVID-19, RdRP Inhibitor, RNA-dependent RNA Polymerase inhibitor, Rouault, SARS-CoV-2, Tempol

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology

Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response

The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy...

Published: 4/22/2025 | Inventor(s): Barbara Felber, George Pavlakis

Keywords(s): CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines, TherapeuticArea > Infectious Disease

Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method

Abstract: DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab...

Published: 5/15/2025 | Inventor(s): Bin Guan, Robert Hufnagel

Keywords(s): Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus

Category(s): TherapeuticArea > Oncology, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Therapeutics Against Pathogenic Coronaviruses

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available...

Published: 4/22/2025 | Inventor(s): Melvin DePamphilis, Matthew Frieman, Arup Chakraborty

Keywords(s): CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...

Published: 4/22/2025 | Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan

Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...

Published: 5/14/2025 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

The Use of Emetine for the Treatment of SARS-CoV-2 Infection

This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...

Published: 10/28/2024 | Inventor(s): Mark Henderson, Juan Marugan, Andreas Dulcey Garcia, Xin Hu, Marc Ferrer-Alegre, Noel Southall

Keywords(s): Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX

Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Research Materials

Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection

The ongoing COVID-19 pandemic, caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an immense public health, social, and economic burden. Variants of concern continue to emerge that have increased transmissibility, pathogenicity, or both and that reduce the effectiveness of current therapeutics and vaccines. Thus, there is...

Published: 10/28/2024 | Inventor(s): Patrizia Farci, Kamille West, Peng Zhang, Paolo Lusso, Zhaochun Chen

Keywords(s): antibodies, Cure, Disease, monoclonal, Prevent, SARS-CoV-2

Category(s): Collaboration Sought > Collaboration

Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use

Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread....

Published: 10/28/2024 | Inventor(s): Shirin Munir, Cindy Luongo, Peter Collins, Cyril Le Nouen, Xueqiao Liu, Ursula Buchholz

Keywords(s): 2, ACUTE, Attenuated, B/HPIV3, BOVINE/HUMAN, chimeric, CORONAVIRUS, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, GLYCOPROTEIN, PIV3, respiratory, S, SARS-CoV-2, SEVERE, spike, Syndrome

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Research Materials

1 2